For over 70 years, almost every drug approved for schizophrenia has modulated dopamine signalling, thus only addressing some symptoms and having notable side effects. Here, Coyle and Paul discuss drugs with promising new mechanisms under development for schizophrenia, including those targeting glutamatergic and cholinergic signalling.
- Joseph T. Coyle
- Steven M. Paul
